These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 9742778

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J, Collaborative Study Group.
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients.
    Sulikowska B, Olejniczak H, Muszyńska M, Odrowaz-Sypniewska G, Gaddi A, Savini C, Cicero AF, Laghi L, Manitius J.
    Am J Nephrol; 2006 Nov; 26(6):621-8. PubMed ID: 17191008
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 10. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
    Cha JJ, Kang YS, Hyun YY, Han SY, Jee YH, Han KH, Han JY, Cha DR.
    Life Sci; 2013 Jun 21; 92(23):1118-24. PubMed ID: 23643633
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
    J Med Assoc Thai; 2006 Feb 21; 89(2):170-7. PubMed ID: 16579002
    [Abstract] [Full Text] [Related]

  • 17. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes.
    Chuahirun T, Khanna A, Kimball K, Wesson DE.
    Am J Kidney Dis; 2003 Jan 21; 41(1):13-21. PubMed ID: 12500217
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
    Ficociello LH, Perkins BA, Silva KH, Finkelstein DM, Ignatowska-Switalska H, Gaciong Z, Cupples LA, Aschengrau A, Warram JH, Krolewski AS.
    Clin J Am Soc Nephrol; 2007 May 21; 2(3):461-9. PubMed ID: 17699452
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.